ARRA::YES::ARRA TAS::75 0850::TAS RECOVERY ACT - TISSUE SOURCE SITE (TSS) IN SUP

ARRA::是::ARRA TAS::75 0850::TAS 恢复法案 - SUP 中的组织源站点 (TSS)

• 批准号: 8166070
• 负责人: ROBERT PENNY
• 金额: $ 549.02万
• 依托单位: INTERNATIONAL GENOMICS CONSORTIUM
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-28 至 2012-02-23
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166070
• 关键词: Atlases; Blood; Cell Nucleus; Clinical Data; Collection; Consent; Contractor; Copy Number Polymorphism; DNA; Data; Diagnosis; Enrollment; Ensure; Excision; Freezing; Genes; Institution; MicroRNAs; Molecular; Mutation Analysis; Necrosis; Patients; Process; Protocols documentation; Qualifying; Quality Control; Recovery; Research; Resources; Sampling; Series; Shipping; Ships; Single Nucleotide Polymorphism; Site; Source; Time; Tissues; biobank; cancer diagnosis; cancer genome; clinical research site; epigenomics; follow-up; programs; prospective; tumor

TCGA has historically relied on retrospectively collected biospecimens. These tissues were accrued by dozens of TSSs around the world through a series of subcontracts managed through the prime contractor at SAIC-Frederick. TSSs included clinical sites, academic institutions as well as commercial companies with biorepositories. Retrospective samples have been invaluable sources of tissue and clinical data, often including long term follow-up. However, the rigorous biospecimen quality, including amount of tissue needed (between 100-150mg), percent of tumor nuclei (at least 70%) and low amount of necrosis (less than 30%) has posed challenges, requiring TCGA to look also at prospective collections. The purpose of this project is to establish Tissue Source Site (TSS) networks capable of delivering clinically annotated biospecimens through either/both retrospective and prospective collections. The tissues and clinical data will be delivered to one of TCGA¿s Biospecimen Core Resource(s) (BCR) for storage, quality control, processing into molecular analytes, and other research efforts. Ultimately, the samples will be characterized for copy number variation, single nucleotide polymorphisms, epigenomic profiles, gene and miRNA expression and mutation analysis.

TCGA 历来依赖于回顾性收集的生物样本，这些组织是通过 SAIC-Frederick 的总承包商管理的一系列分包合同收集的，这些分包合同包括临床场所、学术机构以及拥有生物样本库的商业公司。回顾性样本是组织和临床数据的宝贵来源，通常包括长期随访。然而，严格的生物样本质量，包括所需的组织数量（之间）。 100-150mg）、细胞核肿瘤百分比（至少 70%）和低坏死量（低于 30%）提出了挑战，要求 TCGA 还关注未来的收集。该项目的目的是建立组织源站点。 (TSS) 能够通过回顾性和前瞻性收集提供临床注释的生物样本的网络。组织和临床数据将传送到 TCGA 之一。用于存储、质量控制、加工成分子分析物和其他研究工作的生物样本核心资源 (BCR) 最终，将对样本进行拷贝数变异、单核苷酸多态性、表观基因组图谱、基因和 miRNA 表达的表征。突变分析。